Literature DB >> 29269116

Epigenetic regulation in medulloblastoma.

Jiaqing Yi1, Jiang Wu2.   

Abstract

Medulloblastoma is the most common malignant childhood brain tumor. The heterogeneous tumors are classified into four subgroups based on transcription profiles. Recent developments in genome-wide sequencing techniques have rapidly advanced the understanding of these tumors. The high percentages of somatic alterations of genes encoding chromatin regulators in all subgroups suggest that epigenetic deregulation is a major driver of medulloblastoma. In this report, we review the current understanding of epigenetic regulation in medulloblastoma with a focus on the functional studies of chromatin regulators in the initiation and progression of specific subgroups of medulloblastoma. We also discuss the potential usage of epigenetic inhibitors for medulloblastoma treatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29269116      PMCID: PMC5828953          DOI: 10.1016/j.mcn.2017.09.003

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  150 in total

1.  Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Authors:  Jodi A Muscal; Kathleen A Scorsone; Linna Zhang; Jeffrey A Ecsedy; Stacey L Berg
Journal:  Invest New Drugs       Date:  2012-06-06       Impact factor: 3.850

2.  Targeting the enhancer of zeste homologue 2 in medulloblastoma.

Authors:  Irina Alimova; Sujatha Venkataraman; Peter Harris; Victor E Marquez; Paul A Northcott; Adrian Dubuc; Michael D Taylor; Nicholas K Foreman; Rajeev Vibhakar
Journal:  Int J Cancer       Date:  2012-07-30       Impact factor: 7.396

Review 3.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

Review 4.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

5.  Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.

Authors:  BaoHan T Vo; Chunliang Li; Marc A Morgan; Ilan Theurillat; David Finkelstein; Shaela Wright; Judith Hyle; Stephanie M C Smith; Yiping Fan; Yong-Dong Wang; Gang Wu; Brent A Orr; Paul A Northcott; Ali Shilatifard; Charles J Sherr; Martine F Roussel
Journal:  Cell Rep       Date:  2017-03-21       Impact factor: 9.423

6.  Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Authors:  Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

7.  Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation.

Authors:  M Calao; E O Sekyere; H J Cui; B B Cheung; W D Thomas; J Keating; J B Chen; A Raif; K Jankowski; N P Davies; M V Bekkum; B Chen; O Tan; T Ellis; M D Norris; M Haber; E S Kim; J M Shohet; T N Trahair; T Liu; B J Wainwright; H F Ding; G M Marshall
Journal:  Oncogene       Date:  2012-08-20       Impact factor: 9.867

8.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

9.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

10.  Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy.

Authors:  Sonia Coni; Laura Antonucci; Davide D'Amico; Laura Di Magno; Paola Infante; Enrico De Smaele; Giuseppe Giannini; Lucia Di Marcotullio; Isabella Screpanti; Alberto Gulino; Gianluca Canettieri
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more
  8 in total

Review 1.  Developmental origins and oncogenic pathways in malignant brain tumors.

Authors:  Q Richard Lu; Lily Qian; Xianyao Zhou
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-04-03       Impact factor: 5.814

Review 2.  Medulloblastoma epigenetics and the path to clinical innovation.

Authors:  Amanda R Haltom; Stephanie A Toll; Donghang Cheng; Shinji Maegawa; Vidya Gopalakrishnan; Soumen Khatua
Journal:  J Neurooncol       Date:  2020-08-20       Impact factor: 4.130

Review 3.  DNMT1 and miRNAs: possible epigenetics footprints in electromagnetic fields utilization in oncology.

Authors:  Mohadeseh Shayeghan; Flora Forouzesh; Alireza Madjid Ansari; Mohammad Amin Javidi
Journal:  Med Oncol       Date:  2021-09-08       Impact factor: 3.064

4.  PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma.

Authors:  Jiaqing Yi; BongWoo Kim; Xuanming Shi; Xiaoming Zhan; Q Richard Lu; Zhenyu Xuan; Jiang Wu
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

Review 5.  Modeling human brain tumors in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.

Authors:  Uswa Shahzad; Michael S Taccone; Sachin A Kumar; Hidehiro Okura; Stacey Krumholtz; Joji Ishida; Coco Mine; Kyle Gouveia; Julia Edgar; Christian Smith; Madeline Hayes; Xi Huang; W Brent Derry; Michael D Taylor; James T Rutka
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

6.  Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.

Authors:  Nagendra K Chaturvedi; Sidharth Mahapatra; Varun Kesherwani; Matthew J Kling; Mamta Shukla; Sutapa Ray; Ranjana Kanchan; Naveenkumar Perumal; Timothy R McGuire; J Graham Sharp; Shantaram S Joshi; Don W Coulter
Journal:  BMC Cancer       Date:  2019-11-06       Impact factor: 4.430

Review 7.  Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma.

Authors:  Han Zou; Brad Poore; Alberto Broniscer; Ian F Pollack; Baoli Hu
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

Review 8.  The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.

Authors:  David R Ghasemi; Gudrun Fleischhack; Till Milde; Kristian W Pajtler
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.